Buchumschlag

A multicenter prospective, randomized, placebo-controlled phase II/III trial for preemptive acute graft-versus-host disease therapy

Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17) was tested together with preemptive predniso...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Mischak-Weissinger, Eva Maria (VerfasserIn) , Metzger, Jochen (VerfasserIn) , Schleuning, Michael (VerfasserIn) , Schmid, Christoph (VerfasserIn) , Messinger, Diethelm (VerfasserIn) , Beutel, Gernot (VerfasserIn) , Wagner-Drouet, Eva-Maria (VerfasserIn) , Schetelig, Johannes (VerfasserIn) , Baurmann, Herrad (VerfasserIn) , Rank, Andreas (VerfasserIn) , Stolzl, Friedrich (VerfasserIn) , Schäfer-Eckart, Kerstin (VerfasserIn) , Westphal, Karin (VerfasserIn) , Bethge, Wolfgang (VerfasserIn) , Harsdorf, S. von (VerfasserIn) , Bunjes, Donald W. (VerfasserIn) , Heidenreich, Daniela (VerfasserIn) , Klein, Stefan (VerfasserIn) , Holler, Ernst (VerfasserIn) , Kreipe, Hans H. (VerfasserIn) , Jonigk, Danny (VerfasserIn) , Türüchanow, Irina (VerfasserIn) , Raad, Julia (VerfasserIn) , Papkalla, Armin (VerfasserIn) , von der Leyen, Heiko (VerfasserIn) , Hambach, Lothar (VerfasserIn) , Hamwi, Iyas (VerfasserIn) , Ehrlich, Steve (VerfasserIn) , Krauter, Jurgen (VerfasserIn) , Stadler, Michael (VerfasserIn) , Ganser, Arnold (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 2021
In: Leukemia
Year: 2021, Jahrgang: 35, Heft: 6, Pages: 1763-1772
ISSN:1476-5551
DOI:10.1038/s41375-020-01059-3
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1038/s41375-020-01059-3
Verlag, kostenfrei, Volltext: https://www.nature.com/articles/s41375-020-01059-3
Volltext
Verfasserangaben:Eva M. Weissinger, Jochen Metzger, Michael Schleuning, Christoph Schmid, Diethelm Messinger, Gernot Beutel, Eva-Maria Wagner-Drouet, Johannes Schetelig, Herrad Baurmann, Andreas Rank, Friedrich Stolzl, Kerstin Schäfer-Eckart, Karin Westphal, Wolfgang Bethge, S. von Harsdorf, Donald W. Bunjes, Daniela Heidenreich, Stefan Klein, Ernst Holler, Hans H. Kreipe, Danny Jonigk, Irina Türüchanow, Julia Raad, Armin Papkalla, Heiko von der Leyen, Lothar Hambach, Iyas Hamwi, Steve Ehrlich, Jurgen Krauter, Michael Stadler, Arnold Ganser
Beschreibung
Zusammenfassung:Acute graft-versus-host disease (aGvHD) contributes to about 50% of transplant-related mortality (non-relapse mortality) after allogeneic hematopoietic stem cell transplantation (HSCT). Here the predictive value of a urinary proteomic profile (aGvHD_MS17) was tested together with preemptive prednisolone therapy. Two-hundred and fifty-nine of 267 patients were eligible for analysis. Ninety-two patients were randomized upon aGvHD_MS17 classification factor above 0.1 to receive either prednisolone (2-2.5 mg/kg, N = 44) or placebo (N = 47; N = 1 randomization failure) for 5 days followed by tapering. The remaining 167 patients formed the observation group. The primary endpoint of the randomized trial was incidence of aGvHD grade II between randomization and day +100 post HSCT. Analysis of the short-term preemptive prednisolone therapy in the randomized patients showed no significant difference in incidence or severity of acute GvHD (HR: 1.69, 95% CI: 0.66-4.32, P = 0.27). Prednisolone as preemptive treatment did not lead to an increase in relapse (20.2% in the placebo and 14.0% in the prednisolone group (P = 0.46)). The frequency of adverse events was slightly higher in the placebo group (64.4% versus 50%, respectively). Taken together, the results of the Pre-GvHD trial demonstrated the feasibility and safety of preemptive prednisolone treatment in the randomized patients.
Beschreibung:"Published online: 20 October 2020".- S. 1763
Gesehen am 26.08.2024
Beschreibung:Online Resource
ISSN:1476-5551
DOI:10.1038/s41375-020-01059-3

Ähnliche Einträge